Research and Markets: Five Year Sales Forecasts for the Pharmaceutical Company - Sanofi-Aventis.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36982) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: sanofi-aventis Pharmaceutical Company Intelligence Report to their offering. Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Principal Operating Results Latest Results EXECUTIVE SUMMARY PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT APPENDIX 1 - FINANCIA L PERFORMANCE APPENDIX 2 - KEY CORORATE EVENTS APPENDIX 3 - KEY AGREEMENTS APPEN DIX Dix , Dorothea Lynde 1802-1887. American philanthropist, reformer, and educator who was a pioneer in the movement for specialized treatment of the mentally ill. Noun 1. 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINTVENTURES APPEN DIX 6 - PRODUCT IN DEX Summary sanofi-aventis ranks third amongst research-based pharmaceutical companies, behind Pfizer and GlaxoSmithKline. This report provides a full review of the company's activities together with sales forecasts for key products to 2010. sanofi-aventis was formed in August 2004, when Sanofi-Synthelabo acquired control of Aventis. Subsequently, on 31st December 2004, Aventis merged with and into sanofi-aventis, with sanofi-aventis as the surviving company surviving company The company that emerges in control following a business combination. The surviving company is generally one of the firms entering the combination but may be a new company formed by the combination. . With total revenues of over EUR EUR In currencies, this is the abbreviation for the Euro. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 27 billion in 2005, the combined entity ranks third amongst research-based pharmaceutical companies behind Pfizer and GlaxoSmithKline. sanofi-aventis is focused on two core areas, pharmaceuticals (principally prescription drugs) and human vaccines. Within the pharmaceutical area, sanofi-aventis is active in the following therapeutic areas: Cardiovascular/Thrombosis, Metabolism, Oncology, Central Nervous System and Internal Medicine (which includes Respiratory/Allergy, Urology urology Medical specialty dealing with the urinary system and male reproductive organs. It traces its origin to medieval lithologists, itinerant healers who specialized in surgical removal of bladder stones. , Arthritis/Osteoporosis and Anti-infectives). Current Growth Drivers In the cardiovascular field, Plavix is sanofi-aventis' second best selling product and has demonstrated strong year-on-year sales increases. The recent approval in Japan for the treatment of stroke (January 2006) will further boost sales and is expected to expand sanofi-avenits' profile within this market. Lantus has achieved remarkable year-on-year growth in an increasingly competitive field, with its once-daily dosing setting it apart from its competitors. The US launch of Lantus in combination with Apidra, scheduled for the first quarter of 2006, is anticipated to further bolster sales, allowing it to make significant gains in the metabolic market. Sales of Actonel for use in the prevention and treatment of postmenopausal post·men·o·paus·al adj. Of or occurring in the time following menopause. postmenopausal Change of life Gynecology adjective Referring to the time in ♀ when menstrual periods stop for ≥ 1 yr osteoporosis and corticosteroid-induced osteoporosis, are showing a steady increase. Estimated peak sales of this product are forecast at over US$1 billion. sanofi pasteur (sanofi-aventis' vaccines subsidiary) is a world leader in the development and marketing of vaccines. 2005 saw three successful launches: Decavac, Menactra and Adacel. sanofi pasteur also has the ability to exploit the expanding influenza market. The following launches are set to drive growth in 2006: Pediacel (polio, pertussis/Hib)' ProQuad (measles, mumps, Rubella rubella or German measles, acute infectious disease of children and young adults. It is caused by a filterable virus that is spread by droplet spray from the respiratory tract of an infected individual. and Varicella varicella: see chicken pox. ); Gardasil (Herpes and genital infections); RotaTeq (rotavirus infections Rotavirus Infections Definition Rotavirus is the major cause of diarrhea and vomiting in young children worldwide. The infection is highly contagious and may lead to severe dehydration (loss of body fluids) and even death. ); Zostavax (Zoster zoster /zos·ter/ (zos?ter) herpes zoster. zos·ter n. See shingles. zoster, See herpes zoster. ) and Menactra (meningitis). This company report provides Latest Results A brief review of the latest report results Executive Summary At a glance understanding of the major trends and events affecting the company Financial Analysis (current year) Detailed P&L and investment review of the latest full year performance Company Strategy Where's the company going and how does it plan getting there? Product/R&D Pipeline Highly detailed monographs organised by therapeutic category. Also covers R&D strategy/pipeline and provides 5-year sales forecasts to 2010 for major launched products where available Appendices 5-year financial assessment Key corporate events Key agreements Infrastructure Major pharmaceutical subsidiaries/joint ventures Product index Companies Mentioned Include: aaiPharma - Acambis plc - Ajinomoto Co Inc - Altana Pharma AG - Amgen - Astellas Pharma Inc - Astex Technology - Atrix Laboratories Inc - Bristol-Myers Squibb - Celera Genomics/Axys Pharmaceuticals - Cephalon Ceph´a`lon n. 1. (Zool.) The head. Inc - Chiron Corporation - Ciphergen Biosystems - Coley coley Noun Brit an edible fish with white or grey flesh [perhaps from coalfish] Pharmaceutical Group Inc. - Crucell NV - Daiichi Sankyo - Dainippon Sumitomo Pharma - Debiopharm SA - Eli Lilly - GlaxoSmithKline - IDM (1) See identity management. (2) (Integrated Device Manufacturer) A company that performs every step of the chip-making process, including design, manufacture, test and packaging. Examples of IDMs are Intel, AMD, Motorola, IBM, TI and Lucent. Pharma Inc - ImmunoGen Inc - King Pharmaceuticals Inc - Millennium Pharmaceuticals Inc - Novo Nordisk - Pfizer - Prasco Laboratories - Procter & Gamble - Regeneron Pharmaceuticals Inc - Roche/Genentech - SAS Institute - Shionogi - Teva Pharmaceutical Industries Teva Pharmaceutical Industries Ltd. (Hebrew: טבע תעשיות פרמצבטיות בע"מ), NASDAQ: TEVA is an international pharmaceutical company headquartered in Ltd - VaxGen Inc - Zealand Pharmaceuticals A/S For more information visit http://www.researchandmarkets.com/reports/c36982 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion